Clinical trial
A Multi-Center, Open-Label, Randomized Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
NCT07894328 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Open-Label, Randomized Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- November 20, 2026
- Completion date
- September 30, 2031
- Enrollment
- 1,050 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer
Lead sponsor's other trials
Jiangsu HengRui Medicine Co., Ltd., most recent start first.
+567 more trials See the organization page
Similar trials
Same condition (Breast Neoplasms) and phase, most recent start first.
+1,149 more trials See the condition page